Please login to the form below

Not currently logged in
Email:
Password:

US generics face competition from India

Indian companies have accounted for 35 per cent of all abbreviated new drug application approvals so far this year

Indian companies have accounted for 35 per cent of all abbreviated new drug application (ANDA) approvals so far this year, according to industry information portal, fiercepharma.com. Besides Ranbaxy, which is under Food and Drug Administration (FDA) investigation for falsifying data on its applications, all of the top Indian drugmakers have maintained or improved their approval rates. Sun Pharma received 30 ANDA approvals in 2008, up from 20 in 2007, and Wockhardt was awarded 18 in 2008, against 13 the previous year. Dr Reddy's obtained 14 approvals in 2008, from 13 in 2007. Meanwhile, Flamingo Pharmaceuticals has said it plans to introduce 20 new generics over the next six months, and is making improvements to its distribution network to facilitate its growth.

The rate of approvals is set to continue to increase following the FDA opening an office in Delhi in January. Seven FDA staff will be based in Delhi and three in Mumbai.

9th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics